Abiomed receives PMA (premarket approval) supplement:
This article was originally published in Clinica
Executive Summary
The FDA has given Abiomed a premarket approval supplement for four of its new atrial cannulae featured in the BVS artificial heart system. The cardiac assist device gives temporary circulatory support to failed transplant patients, those who fail to come off cardiopulmonary bypass after heart surgery and those who require right heart support after insertion of an implantable left ventricular assist device.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.